INVESTECH HLDGS (01087) plans to offer approximately 15.19% of its shares for sale, with a maximum of 39,977,600 shares to be sold. The net proceeds are expected to be approximately HK$25.8 million.
Viva China Holdings Limited (01087) announced that on May 13, 2026, the company plans to privately place up to 39,977,600 shares, representing 20% of the existing issued share capital of the company as of the date of this announcement; and the issued share capital of the company will be approximately 16.67% after the placement and issuance of all privately placed shares.
INVESTECH HLDGS (01087) announced that on May 13, 2026, the company plans to issue a maximum of 39.9776 million shares, equivalent to 20% of the existing issued share capital of the company as of the date of the announcement; and after the issuance and distribution of all the new shares, the company's issued share capital will increase by approximately 16.67%. The issue price for each share is HK$0.67, which is a discount of approximately 15.19% from the closing price of HK$0.79 on May 13. Assuming all the new shares are fully subscribed, the total amount raised from the issuance will be approximately HK$26.8 million, with an estimated net amount of HK$25.8 million.
The company plans to use the net proceeds from the issuance as follows: 90% for the repayment of outstanding promissory notes and bank loans; and the remaining 10% for general working capital purposes, including employee costs, professional fees, and other operating expenses.
Related Articles
.png)
XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.

Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.

CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.
XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.
.png)
Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.

CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.

RECOMMEND

Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
11/05/2026

HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
11/05/2026

The Chip Stock Frenzy Is Still Accelerating
11/05/2026


